The North America acute intermittent porphyria market is witnessing growth driven by improved recognition of rare metabolic disorders and increasing access to specialized diagnostic and therapeutic solutions. Rising healthcare expenditure, growing awareness among healthcare professionals, and ongoing research into targeted treatments are contributing to the adoption of advanced management...